celecoxib has been researched along with Granulocytic Leukemia, Chronic in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib was tested in combination with imatinib, demonstrating that celecoxib could strengthen the cytotoxicity of imatinib in imatinib-resistant CML cells." | 1.43 | Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. ( Deng, XB; Fang, ZG; Lin, DJ; Liu, LL; Liu, Q; Liu, SS; Long, ZJ; Lu, Y; Zou, Y, 2016) |
| "Treatment with celecoxib also restored GSK3β function and led to down-regulation of β-catenin activity through transcriptional and post-translational mechanisms, two effects likely to contribute to Ph+ cell growth suppression by celecoxib." | 1.43 | Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. ( Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P, 2016) |
| " Therefore, we examined the effect of rapamycin combined with celecoxib on K562 cells in vitro." | 1.40 | Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway. ( Hao, H; Li, J; Li, R; Luo, J; Xue, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Xue, L | 1 |
| Hao, H | 1 |
| Li, R | 1 |
| Luo, J | 1 |
| Lu, Y | 1 |
| Liu, LL | 1 |
| Liu, SS | 1 |
| Fang, ZG | 1 |
| Zou, Y | 1 |
| Deng, XB | 1 |
| Long, ZJ | 1 |
| Liu, Q | 1 |
| Lin, DJ | 1 |
| Riva, B | 1 |
| De Dominici, M | 1 |
| Gnemmi, I | 1 |
| Mariani, SA | 1 |
| Minassi, A | 1 |
| Minieri, V | 1 |
| Salomoni, P | 1 |
| Canonico, PL | 1 |
| Genazzani, AA | 1 |
| Calabretta, B | 1 |
| Condorelli, F | 1 |
| Subhashini, J | 1 |
| Mahipal, SV | 1 |
| Reddanna, P | 1 |
| Zhang, GS | 1 |
| Liu, DS | 1 |
| Dai, CW | 1 |
| Li, RJ | 1 |
5 other studies available for celecoxib and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle Checkpoints; Cell L | 2014 |
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
Topics: Adult; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G1 Phas | 2016 |
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; DNA Damage; Down-Regulation; Fo | 2005 |
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone M | 2006 |